Increased CSF neurogranin concentration is specific to Alzheimer disease

Neurology

Volumn 86, Issue 9, 2016, Pages 829-835

  Wellington, Henrietta ^a,b   Paterson, Ross W ^b   Portelius, Erik ^c   Törnqvist, Ulrika ^c   Magdalinou, Nadia ^b   Fox, Nick C ^b   Blennow, Kaj ^c   Schott, Jonathan M ^b   Zetterberg, Henrik ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; NEUROGRANIN; PRESENILIN 1; TAU PROTEIN; BIOLOGICAL MARKER;

ADULT; AGE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SHY DRAGER SYNDROME; AGED; CEREBROSPINAL FLUID; ENGLAND; MIDDLE AGED; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UPREGULATION;

AGED; ALZHEIMER DISEASE; BIOMARKERS; FEMALE; HUMANS; LONDON; MALE; MIDDLE AGED; NEUROGRANIN; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UP-REGULATION;

EID: 84959502680     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002423     Document Type: Article

References (36)

1. Dekosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimers disease: correlation with cognitive severity. Ann Neurol. 1990; 27: 457-464.
2. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimers disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30: 572-580.
3. Selkoe DJ. Alzheimers disease is a synaptic failure. Science. 2002; 298: 789-791.
4. Scheff SW, Price DA, Dekosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007; 68: 1501-1508.
5. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimers disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm. 1996; 103: 603-618.
6. Represa A, Deloulme JC, Sensenbrenner M, Ben-Ari Y, Baudier J. Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci. 1990; 10: 3782-3792.
7. Guadaño-Ferraz A, Viñuela A, Oeding G, Bernal J, Rausell E. RC3/neurogranin is expressed in pyramidal neurons of motor and somatosensory cortex in normal and denervated monkeys. J Comp Neurol. 2005; 493: 554-570.
8. Zhong L, Gerges NZ. Neurogranin targets calmodulin and lowers the threshold for the induction of long-Term potentiation. PLoS One. 2012; 7: e41275.
9. Zhong L, Cherry T, Bies CE, Florence MA, Gerges NZ. Neurogranin enhances synaptic strength through its interaction with calmodulin. EMBO J. 2009; 28: 3027-3039.
10. Watson JB, Sutcliffe JG, Fisher RS. Localization of the protein kinase C phosphorylation/calmodulin-binding substrate RC3 in dendritic spines of neostriatal neurons. Proc Natl Acad Sci USA. 1992; 89: 8581-8585.
11. Martzen MR, Slemmon JR. The dendritic peptide neurogranin can regulate a calmodulin-dependent target. J Neurochem. 1995; 64: 92-100.
12. Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimers disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005; 7: 103-117.
13. Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimers disease. Int Psychogeriatr. 1998; 10: 11-23.
14. Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimers disease. Brain Res. 2010; 1362: 13-22.
15. Kvartsberg H, Duits FH, Ingelsson M, et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimers disease. Alzheimers Dement. 2015; 11: 1180-1190.
16. De Vos A, Jacobs D, Struyfs H, et al. C-Terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimers disease. Alzheimers Dement. 2015; 11: 1461-1469.
17. Kvartsberg H, Portelius E, Andreasson U, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimers disease patients and healthy controls. Alzheimers Res Ther. 2015; 7: 40.
18. Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimers disease. Brain. 2015; 138: 3373-3385.
19. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimers disease: the IWG-2 criteria. Lancet Neurol. 2014; 13: 614-629.
20. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-259.
21. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011; 76: 1006-1014.
22. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996; 47: 1113-1124.
23. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994; 57: 416-418.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55: 181-184.
25. Gilman S, Wenning G, Low P, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71: 670-676.
26. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996; 46: 922-930.
27. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid Alzheimer profile: easily said, but what does it mean?. Alzheimers Dement. 2014; 10: 713-723.
28. Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015; 86: 1240-1247.
29. Schmidt K, Mattis P, Adams J, Nestor P. Alternate-form reliability of the Dementia Rating Scale-2. Arch Clin Neuropsychol. 2005; 20: 435-441.
30. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
31. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6: 131-144.
32. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3: 32-35.
33. Moore S, Evans LDB, Andersson T, et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015; 11: 689-696.
34. Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P. Changes in amyloid-b and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013; 5: 194re2.
35. Warren JD, Rohrer JD, Schott JM, Fox NC, Hardy J, Rossor MN. Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends Neurosci. 2013; 36: 561-569.
36. Spires-Jones TL, Hyman B. The intersection of amyloid beta and tau at synapses in Alzheimers disease. Neuron. 2014; 82: 756-771